{
    "code": 0,
    "data": [
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "GENERAL",
            "caption": "Rumour verification - Regulation 30(11)",
            "news_body": "Pls find enclosed Clarification on Market Rumour.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab55a024-c2bd-429c-8a63-7626344aa3d5.pdf",
            "news_date": "2026-02-10 10:18:07"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on February 06 2026 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=DC2C078E_C977_40A8_8B05_CBED261F946F_173118.pdf",
            "news_date": "2026-02-06 17:31:29"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Earnings Call Transcript",
            "news_id": "b53ced32-741d-4dd7-b758-dc622d6fa858",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb27f929-a2a1-4ecf-a6b8-4c3c9750cf12.pdf",
            "news_date": "2026-02-05 11:05:30",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Earnings Call Transcript",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb27f929-a2a1-4ecf-a6b8-4c3c9750cf12.pdf",
            "news_date": "2026-02-05 11:05:30"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Participation In Investor Conference",
            "news_body": "Pls find enclosed intimation w.r.t Participation in Investor Conference",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a29b63c5-9723-4530-b9dd-9761a4c85e02.pdf",
            "news_date": "2026-02-02 10:51:31"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pls find enclosed newspaper cuttings of Financial results published.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b35b348d-9ec5-40ac-8f68-378a575fc3df.pdf",
            "news_date": "2026-02-02 10:32:48"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pls find enclosed Audio recording of Earnings call conducted on 30th January 2026",
            "news_id": "9d442ca3-826e-4f75-a7fe-fa04deb228c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5062da09-f6b0-4e57-8d61-dd6a1fe77061.pdf",
            "news_date": "2026-01-30 17:44:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pls find enclosed Audio recording of Earnings call conducted on 30th January 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5062da09-f6b0-4e57-8d61-dd6a1fe77061.pdf",
            "news_date": "2026-01-30 17:44:28"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Of Vesting And Cash Settlement Of Stock Appreciation Rights (Sars) And Cancellation Of Employee Stock Options (Esops)",
            "news_body": "Pls find enclosed Intimation of vesting of SARs and cancellation of ESOPs",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd7af6a6-225b-4698-83c2-c398bdc4939f.pdf",
            "news_date": "2026-01-30 15:18:54"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Board Meeting Outcome",
            "news_body": "Pls find enclosed Board Meeting Outcome",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=068bc147-7269-4565-b3d2-fa223bce93bd.pdf",
            "news_date": "2026-01-30 15:07:26"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For Quarter Ended 31St December 2025.",
            "news_body": "Pls find enclosed results for quarter ended 31st December 2025.",
            "news_id": "f0718880-bc9a-447b-b16e-6ab2b8c3de1d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62f9a571-200b-4472-bb3f-3a7a1cd649cc.pdf",
            "news_date": "2026-01-30 15:03:57",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For Quarter Ended 31St December 2025.",
            "news_body": "Pls find enclosed results for quarter ended 31st December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62f9a571-200b-4472-bb3f-3a7a1cd649cc.pdf",
            "news_date": "2026-01-30 15:03:57"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "GENERAL",
            "caption": "Rumour verification - Regulation 30(11)",
            "news_body": "Clarification on News Item Appearing in Reuters",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d5d4951-fe2a-420f-a8c8-fdb9a79b7f0c.pdf",
            "news_date": "2026-01-20 10:19:30"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "Pls find enclosed herewith Intimation w.r.t Formation of Subsidiary",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7ab00ff-85dd-44cc-9fde-f97b19a11776.pdf",
            "news_date": "2026-01-13 15:47:31"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pls find enclosed Investor Call Intimation",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0569425d-2803-4c51-a815-b0de3a8a7f37.pdf",
            "news_date": "2026-01-12 15:48:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter Ended 31St December 2025.",
            "news_body": "Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 inter alia to consider and approve Unaudited Financial Results for quarter ended 31st December 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d67c3689-de82-4978-ba41-93c313c2cda6.pdf",
            "news_date": "2026-01-12 11:54:38"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Pls find enclosed Certificate as per Reg. 74(5) of SEBI (DP) Regulations 2018.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97a228af-effe-4230-9a13-4a934de2eb70.pdf",
            "news_date": "2026-01-06 14:49:40"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on December 31 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16176FD9_AAA7_4CDE_9447_16B632C41951_180810.pdf",
            "news_date": "2025-12-31 18:08:15"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on December 30 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15803C95_A2F4_4A5A_9B17_D15DEE9EC23D_180226.pdf",
            "news_date": "2025-12-30 18:03:06"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "PFA Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b42dd71b-29e8-4010-8b96-3c282f899f69.pdf",
            "news_date": "2025-12-26 09:48:06"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "PFA Press Release",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ad9a96e-986e-4a40-9aee-a8dea46820c9.pdf",
            "news_date": "2025-12-23 17:07:21"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on December 19 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=A42D17AB_575B_4826_A8EA_8C0A4A249A36_123226.pdf",
            "news_date": "2025-12-19 12:32:31"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on December 10 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58076C95_AB40_4D2B_9C83_F14B53DC2CF3_143616.pdf",
            "news_date": "2025-12-10 14:36:20"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 26 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1B24E76B_1EC0_4CE2_91FF_0BF2B4EFB330_100418.pdf",
            "news_date": "2025-11-28 10:04:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on November 13 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=F3414306_D29F_47E1_B595_F42ECD6ABB54_150605.pdf",
            "news_date": "2025-11-13 15:06:13"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call",
            "news_id": "89281a08-e235-42f3-a0ae-808795c52647",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e375f416-b0e8-4573-987d-98acbe50ee81.pdf",
            "news_date": "2025-11-06 08:53:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e375f416-b0e8-4573-987d-98acbe50ee81.pdf",
            "news_date": "2025-11-06 08:53:09"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "PFA Newspaper Publication of Financial Results",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23c12326-f809-4e5f-9331-fdd90f4eb760.pdf",
            "news_date": "2025-11-04 12:30:38"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 3rd November 2025",
            "news_id": "63bedeb9-3de0-446b-a942-1d3174f2d050",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3e8b4fc-86ad-4566-b08b-d98d4f7cb04e.pdf",
            "news_date": "2025-11-03 16:37:02",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 3rd November 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3e8b4fc-86ad-4566-b08b-d98d4f7cb04e.pdf",
            "news_date": "2025-11-03 16:37:02"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Registered Office Address",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Registered Office Address",
            "news_body": "PFA Intimation w.r.t change in registered office address",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86913d9c-bde8-4628-8234-51002af3992c.pdf",
            "news_date": "2025-11-03 15:27:04"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Corporate Action- Record Date Fixation",
            "news_body": "PFA Board meeting outcome w.r.t fixation of record date",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b398220-5489-435a-8d2a-65990039b2f8.pdf",
            "news_date": "2025-11-03 13:32:10"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "PFA Dividend and Record Date Announcement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75d98946-ec16-4d4f-a863-f9b3b59bfaf2.pdf",
            "news_date": "2025-11-03 13:31:28"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025",
            "news_body": "PFA Unaudited Financial Results for 30.09.2025",
            "news_id": "5f60c872-66d3-4432-9ff4-f69eefd51b82",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3ae3f4a-9a49-4da7-97c8-29fdbdce241d.pdf",
            "news_date": "2025-11-03 13:25:33",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025",
            "news_body": "PFA Unaudited Financial Results for 30.09.2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3ae3f4a-9a49-4da7-97c8-29fdbdce241d.pdf",
            "news_date": "2025-11-03 13:25:33"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Board Meeting Outcome",
            "news_body": "PFA Board Meeting Outcome",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=083915a0-198f-4a15-81f8-5a0862641d11.pdf",
            "news_date": "2025-11-03 13:21:26"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "Corporate Action- Fixation Of Record Date For 1St Interim Dividend",
            "news_body": "Board in its meeting scheduled to be held on 3rd November 2025 will consider fixation of record date for the purpose of 1st Interim Dividend for FY 2026.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f3b8c34-8d25-48a6-9598-fa74dba61605.pdf",
            "news_date": "2025-10-24 10:02:16"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board to consider Dividend",
            "news_body": "Board in its meeting scheduled to be held on 3rd November 2025 will consider declaration of 1st Interim Dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96beb922-bb50-4921-8035-832527c54800.pdf",
            "news_date": "2025-10-24 09:56:53"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Update on board meeting",
            "news_body": "Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve Update on board meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d24fd98b-5025-4400-8541-b5fbe08f1ed8.pdf",
            "news_date": "2025-10-24 09:49:03"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pls find enclosed Investor Call Intimation",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6025867-f043-4070-8f76-05a0012df369.pdf",
            "news_date": "2025-10-08 16:47:05"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Board Meeting Scheduled To Be Held On 3Rd November 2025.",
            "news_body": "Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve Unaudited consolidated and standalone financial results for the second quarter and half year ended 30th September 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39a099c3-79aa-4d0f-ac7e-a0a67e969363.pdf",
            "news_date": "2025-10-08 12:41:54"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Submission Of Sustainability Report For FY 2025 Prepared As Per GRI Standards\r\n",
            "news_body": "Please find enclosed herewith Sustainability Report for FY 2025 prepared in accordance with the Global Reporting Initiative (GRI) Standards.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa863129-3a56-4383-9650-ebd6770bb235.pdf",
            "news_date": "2025-10-08 12:12:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Pls find enclosed herewith Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dcc50e0-5b30-4d5e-ab81-238e9d91cdf8.pdf",
            "news_date": "2025-10-08 11:53:19"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on October 03 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=474C04EB_8204_456F_B89A_596D221BDE45_171702.pdf",
            "news_date": "2025-10-03 17:17:08"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on October 03 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06D7944F_7BA1_4268_98F8_7F59AB7DB01D_151209.pdf",
            "news_date": "2025-10-03 15:12:14"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on September 25 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1AAD1BA2_0C15_4BF4_B803_39206A3E2729_103856.pdf",
            "news_date": "2025-09-26 10:39:00"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "PFA Intimation w.r.t Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb669a9e-ef84-4449-8b18-6f5120c5bf12.pdf",
            "news_date": "2025-09-25 14:01:50"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on September 16 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1AA14E8D_3DFA_4E5F_A870_6B636E1C4BB7_104058.pdf",
            "news_date": "2025-09-16 10:41:01"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on September 10 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7E584A4A_41C0_47BF_B9E9_3E47C9C2CE2D_150216.pdf",
            "news_date": "2025-09-10 15:02:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pls find enclosed Newspaper Advertisement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01dc3431-d7ba-41a7-abdd-1d935894daac.pdf",
            "news_date": "2025-09-08 12:40:27"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Participation In Investor Conference",
            "news_body": "Please find enclosed intimation w.r.t Participation in Investor Conference.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce4ae30a-1285-4f39-a353-de72c0b9a0aa.pdf",
            "news_date": "2025-09-02 09:05:42"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "PFA Intimation Under Regulation 30 Of SEBI LODR",
            "news_body": "Pls find enclosed Intimation under Regulation 30 of SEBI LODR Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d53753d-d343-4236-9c5a-a91cb44b0bc1.pdf",
            "news_date": "2025-08-20 21:33:52"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call held on 28th July 2025.",
            "news_id": "ad1e0039-0ecb-4ce1-acc3-5fc334700cb2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f4616fe-ef4e-4b4e-847a-c120c78b6669.pdf",
            "news_date": "2025-07-31 11:06:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pls find enclosed Written Transcript of Earnings Call held on 28th July 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f4616fe-ef4e-4b4e-847a-c120c78b6669.pdf",
            "news_date": "2025-07-31 11:06:28"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "PFA newspaper publication of results for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e138697-4120-42c4-b1db-f64f379960f5.pdf",
            "news_date": "2025-07-29 11:37:38"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio Link of Investor Call.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b119b541-1b6e-4cd8-93c5-7bba5d7c3488.pdf",
            "news_date": "2025-07-28 17:23:37"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "PFA ESOP Allotment announcement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b790c904-bda6-4c32-8c68-d5314690e925.pdf",
            "news_date": "2025-07-28 15:34:46"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cba4b25-4440-4484-b8c2-a0b36df44816.pdf",
            "news_date": "2025-07-28 15:05:26"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter Ended 30.06.2025",
            "news_body": "PFA Unaudited Financial Results for quarter ended 30.06.2025.",
            "news_id": "75942d6e-e128-48ee-9775-4048733c338f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf818b5-e94c-4440-983a-30cdf70e514c.pdf",
            "news_date": "2025-07-28 14:59:53",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter Ended 30.06.2025",
            "news_body": "PFA Unaudited Financial Results for quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cf818b5-e94c-4440-983a-30cdf70e514c.pdf",
            "news_date": "2025-07-28 14:59:53"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Pls find enclosed Voting Results pursuant to Regulation 44 of SEBI LODR Regulations and Scrutinizers Report",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=858abe1e-7a71-47d2-86be-500361cd8ea8.pdf",
            "news_date": "2025-07-18 15:23:04"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Please find enclosed Proceedings of AGM pursuant to Regulation 30 of SEBI LODR Regulations 2015.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fcef7b74-b1ec-4013-b993-5cd50f741c9f.pdf",
            "news_date": "2025-07-17 15:01:30"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "PFA Investor Call Intimation.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4ec9bbe-25ef-4260-90c3-2e48c341e258.pdf",
            "news_date": "2025-07-16 16:13:04"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Board Meeting Scheduled To Be Held On 28Th July 2025 For Approving Unaudited Financial Results For The Quarter Ended 30.06.2025.",
            "news_body": "Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 inter alia to consider and approve Unaudited financial results for the quarter ended 30.06.2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ce502b9-68de-4736-aca4-939ec6b32f9a.pdf",
            "news_date": "2025-07-16 15:56:21"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "PFA Certificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30.06.2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1d7b3f6-fe1c-489a-9500-e6f1718de58f.pdf",
            "news_date": "2025-07-08 09:26:21"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 02 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=152F3F9B_4D56_4CDE_8FA8_1168F9E1F5C3_145103.pdf",
            "news_date": "2025-07-02 14:51:08"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 30 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=AE874A4C_9DB4_4B8D_8244_896BE7E41069_121518.pdf",
            "news_date": "2025-06-30 12:15:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "PFA Intimation w.r.t Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d23dca76-9969-47d8-b53e-3ba97ac78bd1.pdf",
            "news_date": "2025-06-26 10:53:33"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pls. find enclosed Newspaper advertisement of e-voting information of 46th AGM.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a71941fd-0692-4c38-a6df-2bac07917435.pdf",
            "news_date": "2025-06-19 12:00:53"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 19 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D0F17F5E_EB68_4056_B884_CFA3C4DF7557_102608.pdf",
            "news_date": "2025-06-19 10:26:22"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "PFA Annual Report along with BRSR for FY 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d61b5b3-9e41-46a9-ba96-8955cc7674c1.pdf",
            "news_date": "2025-06-18 14:14:44"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "PFA Annual Report for FY 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d052b71a-1a88-4eb9-9613-be4da52ec369.pdf",
            "news_date": "2025-06-18 14:11:06"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 16 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9546D2D7_5D3B_4D6F_A798_D734E7F98F0D_101343.pdf",
            "news_date": "2025-06-17 10:13:46"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pursuant to Reg 47 of SEBI LODR PFA notice published in newspapers in terms of Circular No. 20/2020 dated 5th May 2020 of MCA.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eac35c06-9e36-4071-8277-1489de9c6469.pdf",
            "news_date": "2025-06-16 13:53:30"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting - AGM On 17Th July 2025",
            "news_body": "PFA Intimation w.r.t 46th AGM of the Company scheduled to be held on Thursday 17th July 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7db6817d-2dc2-4ffb-95ec-17e53a748ef1.pdf",
            "news_date": "2025-06-12 12:42:11"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "PFA herewith Annual Secretarial Compliance Report for the year 31st March 2025 pursuant to Regulation 24A 0f SEBI LODR Regulations.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c07bb85a-007d-4a38-bd48-d38bfe878235.pdf",
            "news_date": "2025-05-12 12:14:39"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Earnings Call Transcript",
            "news_id": "cfa518fc-6bb5-49a5-bd26-2302e35e1e62",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5e6cc3b-3f5e-4dcf-8ad2-0eed53ec508b.pdf",
            "news_date": "2025-05-05 15:05:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Earnings Call Transcript",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5e6cc3b-3f5e-4dcf-8ad2-0eed53ec508b.pdf",
            "news_date": "2025-05-05 15:05:18"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "PFA newspaper publication of financial results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b05a4e8f-7cb2-4c50-9e77-c453bdc5c85f.pdf",
            "news_date": "2025-05-02 10:20:14"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 30th April 2025",
            "news_id": "23f46fc5-cc44-4515-a80d-dc789171e19d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d46786a7-3457-4077-8803-ef79b49e5f0b.pdf",
            "news_date": "2025-04-30 18:20:42",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 30th April 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d46786a7-3457-4077-8803-ef79b49e5f0b.pdf",
            "news_date": "2025-04-30 18:20:42"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "PFA Intimation W.R.T Cancellation Of Esops",
            "news_body": "PFA Intimation w.r.t Cancellation of ESOPs",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c556b528-dac4-443e-944f-567c7e91f929.pdf",
            "news_date": "2025-04-30 15:56:56"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Meeting Updates",
            "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
            "news_body": "PFA meeting updates as per Reg 30 of SEBI LODR.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9a2ebc7-a7ed-4941-b421-992fc11c4f28.pdf",
            "news_date": "2025-04-30 15:48:20"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Directorate",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
            "news_body": "PFA Intimation w.r.t re-appointment of Mr. Madhusudan Agrawal.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06919c7d-7b46-4922-b1ac-4011ae671626.pdf",
            "news_date": "2025-04-30 15:42:39"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92f89521-8323-494a-9c60-a34062a874a5.pdf",
            "news_date": "2025-04-30 15:31:08"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "PFA Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2025 Pursuant To Regulation 33 Of SEBI (LODR).",
            "news_body": "PFA Audited Results",
            "news_id": "f9b1e6a0-d127-4db0-abb8-3c96a6e36556",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c209dff-01ae-4656-8d9d-b3db7504ee8b.pdf",
            "news_date": "2025-04-30 15:23:35",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "PFA Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2025 Pursuant To Regulation 33 Of SEBI (LODR).",
            "news_body": "PFA Audited Results",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c209dff-01ae-4656-8d9d-b3db7504ee8b.pdf",
            "news_date": "2025-04-30 15:23:35"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "PFA Intimation w.r.t Investor Call.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cda0b6e8-c535-498f-aa97-84b667452dd7.pdf",
            "news_date": "2025-04-29 16:38:58"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on April 22 2025 for Aayush Agrawal trustee  Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=E86F702C_C941_4CD1_9A4C_82A6F7C84DD8_145531.pdf",
            "news_date": "2025-04-22 14:55:35"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Board Meeting Schedule To Be Held On 30Th April 2025 For Approving Audited Financial Results For The Quarter And Year Ended 31St March 2025",
            "news_body": "Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2025 inter alia to consider and approve Audited Financial results for the quarter and year ended 31st March 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cdcaf425-feea-42fc-a6fe-b32e87afe953.pdf",
            "news_date": "2025-04-22 14:28:24"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on April 03 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=AFC10000_298F_4341_B7F3_AEA7EE5B2447_151624.pdf",
            "news_date": "2025-04-03 15:16:27"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "PFA Intimation of Closure of Trading Window.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a17e688-8b81-475d-98c3-ffb299f0bfd4.pdf",
            "news_date": "2025-03-27 12:08:32"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 24 2025 for Ravi Agrawal trustee Ravi Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=739555BA_EB79_4F2A_B27E_8DC4219485F7_140821.pdf",
            "news_date": "2025-03-24 14:08:37"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation For Capacity Addition Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
            "news_body": "PFA Intimation for Capacity Addition.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=781f1d28-c90d-4003-af86-6db745a5375f.pdf",
            "news_date": "2025-03-20 16:29:21"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 10 2025 for Aayush Agrawal (Trustee Aayush Agrawal Trust)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=562F0FC7_2AB9_4CA0_8011_945449C31A55_100116.pdf",
            "news_date": "2025-03-11 10:01:20"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 10 2025 for Ravi Agrawal (Trustee Ravi Agrawal Trust)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=F761F27F_5ED0_40B3_B5C1_8518131287E1_095939.pdf",
            "news_date": "2025-03-11 09:59:43"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Participation In Investor Conference",
            "news_body": "PFA Intimation w.r.t Participation in Investor Conference.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dbde88f-88fd-47df-b10f-5979313ef6bc.pdf",
            "news_date": "2025-02-20 16:24:29"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General",
            "descriptor": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
            "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
            "news_body": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on February 13 2025 for Aayush Agrawal trustee Aayush Agrawal Trust",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5DC9DB4A_B243_4506_8D71_4C58E865E553_102843.pdf",
            "news_date": "2025-02-14 10:28:47"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Participation In Investor Conference",
            "news_body": "PFA herewith Intimation of Participation in Investor Conference",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f64732f6-9e11-438b-8882-d6b89c05e782.pdf",
            "news_date": "2025-02-07 09:33:00"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Integrated Filing (Financial)",
            "caption": "Integrated Filing (Financial)",
            "news_body": "PFA herewith Integrated Filing (Financials)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b561ad6-3cf2-46b5-b6f4-9662cca0f469.pdf",
            "news_date": "2025-02-05 16:39:01"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Grant Of Stock Appreciation Rights",
            "news_body": "PFA Intimation w.r.t Grant of Stock Appreciation Rights",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=796cefda-71ac-4c7f-ab40-52b631dbe533.pdf",
            "news_date": "2025-02-05 16:17:45"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "GENERAL",
            "caption": "Rumour verification - Regulation 30(11)",
            "news_body": "PFA Intimation of Market Price Movement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1eaa585b-e4fc-47b2-9660-c5f1695bf5f3.pdf",
            "news_date": "2025-02-04 09:53:38"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Written Transcript of Earnings Call conducted on 30th January 2025.",
            "news_id": "e68ca37c-4721-4f47-955d-6e22432becd9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=935d8784-73b0-47a4-acb3-00e8f4ebac68.pdf",
            "news_date": "2025-02-03 16:23:32",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Written Transcript of Earnings Call conducted on 30th January 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=935d8784-73b0-47a4-acb3-00e8f4ebac68.pdf",
            "news_date": "2025-02-03 16:23:32"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "PFA Newspaper Publication of Results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aea2bd36-f581-4a71-91b8-a14a7659c251.pdf",
            "news_date": "2025-01-31 12:56:52"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audio recording of Earnings call conducted on 30th January 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3aa7bfe-c5c7-4e84-a7a7-7028fb4f20a8.pdf",
            "news_date": "2025-01-30 18:13:14"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Cancellation Of Employee Stock Options",
            "news_body": "Cancellation of ESOPs",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31a5078d-5f82-457a-8b06-42d8fcdaa16b.pdf",
            "news_date": "2025-01-30 15:41:59"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024 Pursuant To Reg 33 Of SEBI (LODR)",
            "news_body": "PFA enclosed outcome of Board Meeting for more details.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f959dc2-d663-41bd-8ae7-236a8623e378.pdf",
            "news_date": "2025-01-30 15:37:52"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St December 2024.",
            "news_body": "PFA Results of 31st Dec 2024.",
            "news_id": "29fd1e5e-ab37-4f20-b4e8-338e25da30b5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c389b762-9030-46e2-9785-2ce8f0dba0dc.pdf",
            "news_date": "2025-01-30 15:35:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Nine Months Ended 31St December 2024.",
            "news_body": "PFA Results of 31st Dec 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c389b762-9030-46e2-9785-2ce8f0dba0dc.pdf",
            "news_date": "2025-01-30 15:35:09"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "PFA Intimation of analysts/institutional investors meet.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a93ec318-cd2f-442f-be7a-59cc67339e64.pdf",
            "news_date": "2025-01-17 14:33:16"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Approving Unaudited Financial Results For The Quarter Ended 31St December 2024.",
            "news_body": "AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve Unaudited consolidated & standalone financial results of the Company for the third quarter and nine months ended 31st December 2024",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cc02d4d-1e54-4f1c-8402-cbacbf205bae.pdf",
            "news_date": "2025-01-17 14:16:14"
        },
        {
            "co_code": 13504,
            "bse_code": 532331,
            "isin": "INE031B01049",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "PFA Certificate under Reg 74(5) of SEBI (DP) Regulations.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e076ac46-ef59-4aad-9573-52857c963d34.pdf",
            "news_date": "2025-01-07 16:35:39"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA Earning Call Transcript",
            "news_id": "58ea631a-8ea3-4f92-ba91-680286b703fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca0017a7-cb7c-4b0e-865e-e09358d8b46d.pdf",
            "news_date": "2024-10-30 17:55:47",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "PFA Audior Recording Link of the Investor Call Meeting",
            "news_id": "8899d06d-c6d6-4b40-a164-bacdcb58250d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a82ac20-ddeb-41ba-93d8-0f472fde7285.pdf",
            "news_date": "2024-10-28 18:31:25",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited (Consolidated & Standalone) Financial Results For The Quarter And Half Year Ended 30.09.2024.",
            "news_body": "PFA Results of HI FY25",
            "news_id": "b2a632dc-984f-4dcd-b4ce-b086036b6d48",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf9aa7db-5f4d-4190-af0d-0cf157f0d3aa.pdf",
            "news_date": "2024-10-28 15:51:28",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 30th July 2024",
            "news_id": "03ecef83-2a3b-465e-a60c-36050aae8c04",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abb0b970-f53a-4007-ac6a-cd1d1f4a2a3b.pdf",
            "news_date": "2024-08-02 17:39:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th July 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q1-FY2025.mp3",
            "news_id": "a20a6d0f-c30f-4a25-bbc0-76a5c9dbc0e6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ea3a5fe-d177-4412-902d-a197f348d783.pdf",
            "news_date": "2024-07-30 18:49:42",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter Ended 30.06.2024",
            "news_body": "PFA outcome of Board Meeting",
            "news_id": "60bf5432-0864-4cef-8182-bf6a452e8fd6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0207d4a4-925e-4275-8915-f1c7e21b471c.pdf",
            "news_date": "2024-07-30 15:01:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 2nd May 2024.",
            "news_id": "33ce1bf6-6322-4288-987f-134fa249b008",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a62da3c-8611-46f8-ad58-e259f136d1a5.pdf",
            "news_date": "2024-05-08 14:03:43",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 2nd May 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q4-FY2024.mp3",
            "news_id": "829281aa-8fe6-43d2-8e46-0e8b6dbd9feb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81a65223-88bd-453b-9cc4-a08efdc1de73.pdf",
            "news_date": "2024-05-02 20:33:54",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results-Financial Results For 03,31,2024",
            "news_body": "Outcome of Board Meeting",
            "news_id": "e954c539-68e8-4de0-b25a-9670efed8b42",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87b56f4f-8d55-42ce-9845-5f889c3937d8.pdf",
            "news_date": "2024-05-02 16:39:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call conducted on 31st January 2024.",
            "news_id": "526c8c56-818d-4c13-aa91-a4ef01b88e76",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a47b89b5-e835-47c5-b686-e6d2b61e1fab.pdf",
            "news_date": "2024-02-05 16:49:46",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2024 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:   https://ajantapharma.com//images/EarningsAudio-Q3FY2024.mp3",
            "news_id": "a7d70196-7ff7-4da4-b573-9063a9e5df6c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43de6454-fe17-4ba7-a7bc-63b1e4b77b5e.pdf",
            "news_date": "2024-01-31 19:50:17",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St December 2023",
            "news_body": "Results for Dec 2023",
            "news_id": "aee21e94-2a00-43ce-b533-df38b5fcc931",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=526e6d11-fa74-448e-9896-ce13cdc34d86.pdf",
            "news_date": "2024-01-31 16:12:24",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith Written Transcript of Earnings Call held on 31st October 2023.",
            "news_id": "432cb5a7-cbd4-4ad2-931b-019f6c77ca86",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bd02dde-7d9d-4025-8e5d-610f7b4ec805.pdf",
            "news_date": "2023-11-03 12:15:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st October 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsAudio-Q2FY2024.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "5a5aea31-f53b-455c-b484-c9d8387343a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a2cd9541-eea3-4bc9-a9c9-546d4e768153.pdf",
            "news_date": "2023-10-31 19:24:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Second Quarter And Half Year Ended 30Th September 2023",
            "news_body": "Results for the Second Quarter and Half Year Ended 30th September 2023.",
            "news_id": "8f7ae33d-08b7-43ac-8fb5-82b18bde1058",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2b564d9-f6e1-4bce-9e97-e32da18568e9.pdf",
            "news_date": "2023-10-31 14:15:46",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "PFA herewith written transcript of earnings call held on 27th July 2023.",
            "news_id": "c3558683-9ce4-422c-b31e-49ae55198d01",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b4972d7-306f-4d98-a52b-bdbf9b4f5448.pdf",
            "news_date": "2023-08-02 17:23:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 27th July 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsAudioQ1-2023-24.mp3Written transcript of the same will be submitted in due course.",
            "news_id": "7bd194ca-90af-48f5-84e8-163c84b31e23",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d59261e-c947-4030-bc26-a7398484aeab.pdf",
            "news_date": "2023-07-27 19:04:38",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter Ended 30Th June 2023",
            "news_body": "Enclosed Financial results for quarter ended 30th June 2023.",
            "news_id": "15e34e77-4ff0-48f7-ac1b-cec6f2f4b5aa",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c944b568-5374-42c4-a4ff-6fbea16322c6.pdf",
            "news_date": "2023-07-27 15:59:56",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 5th May 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ4(Jan-Mar)2022-23.pdf.",
            "news_id": "601944a6-4ae1-4761-9215-4e3b99db0284",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1e28fab-5ec4-4504-b771-e71dcd96f458.pdf",
            "news_date": "2023-05-11 12:09:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EAC-Q4-(Jan-Mar)-2022-23.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "f4b3ddae-b813-4cc8-9d76-586e3642b57c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9b2356a-1aac-4ede-a500-b60e4f4b05d5.pdf",
            "news_date": "2023-05-05 20:12:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited (Consolidated & Standalone) Financial Results For The Quarter And Year Ended 31St March 2023",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith following:<BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2023 along with statement of Assets & Liabilities, Cashflow statement and Auditors' report with unmodified opinion;<BR> 4. Investor presentation.",
            "news_id": "e271aeaa-4c1a-4cde-8c63-c05f49bb8407",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=186a93f2-85ba-4e2a-9ccd-0a80e5993cfb.pdf",
            "news_date": "2023-05-05 15:46:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "We hereby inform that at the Board meeting held on Friday, 5th May 2023, Board has inter-alia approved and taken on record the Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2023.<BR> <BR> Board has also approved amendment in the object clause of Memorandum of Association (MOA) to align the same with regulatory requirements. There is no change in the principal business of the Company. This amendment is subject to approval of the shareholders at the ensuing Annual General Meeting.",
            "news_id": "62b539c5-37a0-47e6-8310-e6893e0d0b4e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=684ad1be-1eda-44f1-a5a5-9f7e093cfc56.pdf",
            "news_date": "2023-05-05 15:40:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 2nd February 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link:https://ajantapharma.com//images/EarningsCallTranscriptQ3(Oct-Dec)2022-23.pdf",
            "news_id": "a7673039-cf99-4614-bd78-8fdef98cb28e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42628511-3350-44be-bd69-f28ab239201a.pdf",
            "news_date": "2023-02-13 09:54:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallAudioQ3(Oct-Dec)2022-23.mp3",
            "news_id": "363bcf26-42f1-4129-9775-cb2fa6e257dc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c444d28-f0ee-4978-a297-5d2d3e6c56cf.pdf",
            "news_date": "2023-02-02 10:54:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St December 2022",
            "news_body": "Results for the quarter and nine months ended 31st December 2022",
            "news_id": "a43547c7-54a0-4a9d-820c-34bd05f50966",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=334f7dd3-b18a-4803-9fde-cad75ae7b809.pdf",
            "news_date": "2023-02-01 16:09:11",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited<BR> Financial results for the quarter and nine months ended 31st December 2022. Pursuant to Regulation<BR> 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.<BR> <BR> Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,<BR> 2015, we would like to inform that based on the recommendations of Nomination & Remuneration<BR> Committee meeting held today, Board has also approved the re-appointment of Mr. Yogesh Agrawal<BR> as Managing Director and Mr. Rajesh Agrawal as Joint Managing Director for a further period of five<BR> years from 1st April 2023 upto 31st March 2028, subject to approval of members.",
            "news_id": "7ca0566c-ab1f-49be-934c-0bce506395c4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10aa6900-e036-4d3b-8181-fca2fdb301ce.pdf",
            "news_date": "2023-02-01 15:37:37",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 3rd November 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ2FY23.pdf .",
            "news_id": "dd0d9168-343a-41ac-8131-2276cd930fc0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5bfe024e-353a-4d31-9fc3-7989ed99f58f.pdf",
            "news_date": "2022-11-10 13:07:44",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EC-AudioQ2(Jul-Sep)2022-23.mp3",
            "news_id": "5ea88a8c-839b-41c0-8430-41221e82e182",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b25ae24-3a80-441a-80c6-f26dc9c77af2.pdf",
            "news_date": "2022-11-04 10:32:51",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Second Quarter And Half Year Ended 30Th September 2022",
            "news_body": "Results for second quarter and half year ended 30th September 2022",
            "news_id": "18422a82-7935-4532-a31c-58dfa39f1b7b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d811d70-bd4e-4ebd-93bc-17e55fa7b0ee.pdf",
            "news_date": "2022-11-03 15:57:00",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 3rd November 2022, approved the following:<BR> i. Unaudited Consolidated and Standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022;<BR> ii. Payment of interim dividend of Rs. 7/- (350%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2022-23;<BR> iii. Fixed Monday, 14th November 2022 as the Record date for payment of interim dividend. Interim dividend will be paid on or after 24th November 2022.",
            "news_id": "c83d2425-7e1a-46ea-8aa4-ccf5a9f39042",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cd99034-8a39-4832-9030-f1595e760892.pdf",
            "news_date": "2022-11-03 15:39:53",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th July 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed written transcript of the earnings call held on 28th July 2022 at 5.00 p.m.Further, written transcript has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ1(Apr-Jun)2022-23.pdfThis is for your information and records please.",
            "news_id": "e5f6e05c-52d0-4989-a137-57b53e60e5a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=694ff1ee-1c91-42d0-aeb1-56e94bb44931.pdf",
            "news_date": "2022-08-03 18:35:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 28Th July 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 28th July 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ1(Apr-Jun)2022-23.mp3Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "9883b596-fa12-4ad9-8c22-16d40028760d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2be4010a-e48a-4ba7-9344-9ddcd0c99a35.pdf",
            "news_date": "2022-07-29 10:32:20",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Quarter Ended 30Th June 2022",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2022. Pursuant to Regulation 33 of SEBI LODR Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2022;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> vi. Investors' presentation.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records.",
            "news_id": "6410cc04-81e6-405c-b4d2-fb710e2b7985",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8be1bdd8-c16f-4c74-9e05-bccdd31f458f.pdf",
            "news_date": "2022-07-28 16:19:10",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2022;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iii. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> v. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Standalone Financial Results for the quarter ended 30th June 2022;<BR> vi. Investors' presentation.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records.",
            "news_id": "de917ec5-fd60-4fde-a2b0-92f476e0909d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94f7af8b-bd40-4cb1-9233-234a5498dd95.pdf",
            "news_date": "2022-07-28 16:07:06",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 10th May 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsC allTranscriptQ4(Jan-Mar)2021-22.pdf",
            "news_id": "97964789-f4ec-46ab-98ae-72fbc7b5e771",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7dccf0c6-431c-435b-8830-eb737f332061.pdf",
            "news_date": "2022-05-14 13:09:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 10Th May 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 10th May 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link in the attachment.Written transcript of the same will be submitted in due course.This is for your information and records please.",
            "news_id": "32d139ba-4c85-4427-9582-496301c062c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6bdad93f-0042-47a1-87a4-c7bfdced2147.pdf",
            "news_date": "2022-05-11 10:46:45",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "We hereby inform that at the Board meeting held on Tuesday, 10th May 2022, the Board has interalia:<BR> <BR> a. Approved and taken on record, Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2022;<BR> b. Approved issue of bonus shares in the ratio of 1:2 i.e. One new fully paid-up equity shares of Rs. 2/- each to be issued for every Two equity shares held, subject to approval of shareholders of the Company. Separate disclosure under Regulation 30 is being filed shortly;<BR> c. Recommended re-appointment of M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022) as statutory auditors of the Company for second term of 5 years, from the conclusion of 43rd Annual General Meeting till the conclusion of 48th Annual General Meeting, subject to the approval of the shareholders of the Company.",
            "news_id": "a3414727-9621-4c2d-8af4-d100630ac9c0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6818442d-3b8a-4ffe-b4b9-2d93b2f88704.pdf",
            "news_date": "2022-05-10 14:13:12",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 31st January 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ3(Oct-Dec)2021-22.pdfThis is for your information and records please.",
            "news_id": "3ae13e8d-8931-4c17-b735-ee49e622d9e4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ae34c56-60dc-4710-858a-646de80fce56.pdf",
            "news_date": "2022-02-04 14:26:00",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 31St January 2022",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ3(Oct-Dec)2021-22.mp3",
            "news_id": "86217257-6da2-4fd4-940b-309004df5f4d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ad87c86-7345-49a0-b3cf-2810eed45de9.pdf",
            "news_date": "2022-01-31 19:32:27",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter and nine months ended 31st December 2021;<BR> ii. Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021;<BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2021;<BR> iv. Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2021;<BR> vi. Investors' presentation.<BR> Kindly note that the meeting of the Board of Directors commenced at 1.45 p.m. and concluded at 3.15 p.m. and take the above on your records.",
            "news_id": "81e7e616-c9ba-4045-850f-77e496d4ea5e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2d591b4-c2d6-45f6-b7c2-bce3641d2416.pdf",
            "news_date": "2022-01-31 15:23:32",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ2(Jul-Sep)2021-22.pdf",
            "news_id": "86c68ad4-9a11-4086-b0f4-2b240f4984ec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfa36dca-488e-485b-a90e-0a6a85f2f066.pdf",
            "news_date": "2021-11-08 10:53:33",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ2(Jul-Sep)2021-22.pdf",
            "news_id": "78351fc7-420d-4966-b5e6-af557e2ed1af",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fdc2820-bdc0-415f-a78d-bcad7e96f930.pdf",
            "news_date": "2021-11-08 10:53:08",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 29Th October 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 29th October 2021 at 4.45 p.m. has been uploaded on the Company's website and can be accessed through the link:<BR> <BR> http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ2(Jul-Sep)2021-22.mp3<BR> <BR> This is for your information and records please.",
            "news_id": "cdae5a9f-27bc-493b-9f45-6e1820cb881b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0faa0d09-cf55-4392-9d13-2761149f74f9.pdf",
            "news_date": "2021-10-29 18:57:09",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Dear Sir/Madam,<BR> Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 29th October 2021, approved the following:<BR> i. Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September 2021;<BR> ii. Payment of interim dividend of Rs. 9.50/- (475%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2021-22;<BR> iii. Fixed Wednesday, 10th November 2021 as the Record date for payment of interim dividend. lnterim dividend will be paid on or after Tuesday, 16th November 2021.<BR> <BR> Kindly note that the meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 2.15 p.m. and take the above on your records.<BR> <BR> Kindly take the above on your records.",
            "news_id": "f86bd655-3af7-4f4a-b433-1e12b427e8b5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55675dee-1db8-4743-a220-879eae3218a6.pdf",
            "news_date": "2021-10-29 14:29:05",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 30th July 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 29th July 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallTranscriptQ1(Apr-Jun)2021-22.pdf<BR> <BR> This is for your information and records please.",
            "news_id": "2256ec28-a028-4d81-85df-8c2ef285d99d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3abeab2c-7c26-4694-8608-b8fd068f0f49.pdf",
            "news_date": "2021-08-02 18:48:18",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 29Th July 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call  recording of the earnings call held on 29th July 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ1(Apr-Jun)2021-22.mp3<BR> <BR> Written transcript of the same will be submitted in due course.",
            "news_id": "33484759-1077-4817-aa47-f1fdb06fd064",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b210416-131a-4dd3-a46c-46c2eaba9ac8.pdf",
            "news_date": "2021-07-30 12:04:29",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting",
            "news_body": "At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> i. Press Release being issued on the Results for the quarter ended 30th June 2021;<BR> ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2021; <BR> iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2021;<BR> iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2021;<BR> v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2021;<BR> vi. Investors' presentation.",
            "news_id": "faea63c3-d60d-4449-9b28-8b774b988b26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7c3465f-8400-4a27-ba3b-738e4a418e4a.pdf",
            "news_date": "2021-07-29 16:01:12",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Schedule Of Earnings Conference Call Post Board Meeting",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements ) Regulations 2015, we are enclosing herewith the schedule of Earnings conference call to be<BR> held on 29th July 2021, post Board meeting.<BR> <BR> This is for your information and records please.",
            "news_id": "38d3e8d9-50ab-4876-9a87-3acb5ffc0922",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3721abd-ccb2-408e-b23c-1f5dc3f73af4.pdf",
            "news_date": "2021-07-22 17:50:57",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Further to our communication dated 30th April 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx<BR> <BR> This is for your information and records please.",
            "news_id": "9a0f612a-1fc8-4524-8cb4-e70c5980ffa9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47d035f6-30eb-4976-907b-e1936e216dac.pdf",
            "news_date": "2021-05-04 14:24:30",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On 30Th April 2021",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 30th April 2021 at 5.30 p.m. has been uploaded on the Company's website and can be accessed through the link http://ajantapharma.com/Results.aspx<BR> <BR> Written transcript of the same will be submitted in due course.<BR> <BR> This is for your information and records please.",
            "news_id": "be4d9011-da8b-44b4-b29b-230b98749a0e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b990fce-a821-4b29-9492-818f910aa45e.pdf",
            "news_date": "2021-04-30 20:30:55",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "<BR> Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> <BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 4. Investor's presentation.<BR> <BR> Separate disclosure under Regulation 30 is being filed shortly. <BR> <BR> We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. <BR> <BR> Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. <BR> <BR> Kindly take the above on your records.<BR>",
            "news_id": "e79a560b-5043-4f1b-81e3-cc262a74e801",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e474861e-b71c-45bc-8055-044da64de80d.pdf",
            "news_date": "2021-04-30 16:25:01",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AJANTPHARM",
            "disp": "Ajanta Pharma",
            "bse_code": 532331,
            "isin": "INE031B01049",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting - Approve And Take On Record The Audited (Consolidated & Standalone) Financial Results Of The Company For The Quarter And Year Ended 31St March 2021",
            "news_body": "Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:<BR> <BR> 1. Press Release;<BR> 2. Audited Consolidated Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 3. Audited Standalone Financial Results for the quarter and year ended 31st March 2021 along with Auditors' report with unmodified opinion;<BR> 4. Investor's presentation.<BR> <BR> Separate disclosure under Regulation 30 is being filed shortly. <BR> <BR> We shall inform in due course, date of the 42nd Annual General Meeting to be held for the year ended 31st March 2021. <BR> <BR> Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 4.00 p.m. <BR> <BR> Kindly take the above on your records.",
            "news_id": "88bb8263-73e8-4deb-a4c0-8e649ccaab42",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=816eb5c1-a96e-4f86-a9cd-a4382425e9ad.pdf",
            "news_date": "2021-04-30 16:09:17",
            "seo": "ajanta-pharma-ltd",
            "ltp": 2907.8,
            "ch": 16.5,
            "pch": 0.5706775498910525,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 8124,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}